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Obacunone activates the Nrf2-dependent
antioxidant responses
Dear Editor,
The transcription factor nuclear factor erythroid 2-related
factor 2 (Nrf2) plays a crucial role in human antioxidant
defense response against environmental insults. Small
molecular chemical activators of Nrf2 can confer protection
against oxidative insults and inhibit the progression of dis-
eases related to oxidative stress. Here, we identiﬁed oba-
cunone as a novel activator of Nrf2 by decreasing Nrf2
ubiquitination and increasing its stability. In support of these
ﬁndings, the systemic administration of obacunone strongly
inhibits bleomycin-induced lung ﬁbrosis in mice. Therefore,
obacunone may also provide antioxidant protection for
humans against tissue damage caused by oxidative insults.
The nuclear factor-erythroid 2-related factor (Nrf2) is a
redox-sensitive transcriptional factor, activity of which is
tightly regulated by cytosolic protein Kelch-like ECH-asso-
ciated protein 1 (Keap1) (Chen et al., 2009). The keap1-Nrf2
signaling pathway is a master antioxidant defense mecha-
nism against environmental insults. In the absence of
oxidative stress, Nrf2 is bound to Keap1 and ubiquitinated by
a cul3-based E3 ligase, leading to proteasome-mediated
degradation (Cullinan et al., 2004). In response to oxidative
stress, the E3 ubiquitin ligase is inactivated through the
modiﬁcation of critical cysteine residues of Keap1, thereby
allowing the accumulation of Nrf2 and its translocation into
the nucleus (Zhang et al., 2004; Villeneuve et al., 2010). The
activated Nrf2 exerts an intracellular antioxidant defense
response through transcriptional activation of many genes
including phase II detoxifying enzymes, drug transporters,
antioxidant enzymes, and proteins involved in the repair and
removal of damaged macromolecules (Villeneuve et al.,
2010), thereby neutralizing reactive oxygen species (ROS),
detoxifying harmful chemicals, and maintaining redox
homeostasis. Therefore, the Nrf2 activation with small
molecular chemicals can enhance body’s defense against
oxidative insults.
Several small molecular chemical activators of Nrf2 have
already been identiﬁed, most of which are plant-derived
chemicals such as sulforaphane, tanshinone I, curcumin,
BHA (Jeong et al., 2006; Nishinaka et al., 2007; Zhang and
Hannink, 2003). Using in vivo mouse models, the Nrf2 acti-
vation induced by these activators has been shown to inhibit
the progression of diseases related to oxidative stress,
including diabetes, cancer, cardiovascular diseases, neu-
rodegenerative diseases, pulmonary ﬁbrosis, and inﬂam-
matory diseases (Chapple et al., 2012). Conversely, the
Nrf2-knockout mice are prone to acute damages and tumor
formation induced by various harmful chemicals (Ramos-
Gomez et al., 2001; Wang et al., 2008). All these data
demonstrate that Nrf2 can be used as a drug target for
prevention and therapy of diseases related to oxidative
stress. Therefore, the identiﬁcation of novel and non-toxic
Nrf2 activators is important for the development of effective
dietary supplements or therapeutic drugs that protect
humans against oxidative damage.
Employing the MDA-MB-231 cells stably transfected with
an ARE-luciferase reporter as a screening platform (Chen
et al., 2016), we identiﬁed that obacunone could induce the
expression of the ARE-dependent luciferase gene in a dose-
dependent manner (Fig. S1). Obacunone is a small molec-
ular compound derived from citrus fruits with a higher con-
tent in seeds. Published studies indicate that obacunone can
inhibit cancer proliferation and has some therapeutic effects
on cardiovascular diseases (Poulose et al., 2006; Yoon
et al., 2014). As expected, the protein levels of Nrf2 were
increased in various cell types after obacunone treatment,
while Keap1 levels remained constant in MDA-MB-231 cells
(Fig. 1A–C). Consistent with this ﬁnding, the mRNA levels of
Nrf2 target genes such as NQO1, Mrp2, and HO-1 were
increased in these cells after being treated with increasing
doses of obacunone (Fig. 1D and 1E). To evaluate the
impact of obacunone on Nrf2-dependent antioxidant effect,
MDA-MB-231 cells were pretreated with obacunone for 8 h,
and then challenged with H2O2 for an additional 12 h. Pre-
treatment with obacunone reduced ROS levels signiﬁcantly
(Fig. 1F). Therefore, obacunone can effectively protect cells
from oxidative stress by activating the Nrf2 pathway.
To investigate the mechanism how obacunone increases
the protein levels of Nrf2, we measured the half-life of Nrf2
protein in the absence or presence of obacunone. At the
indicated time points after the addition of cycloheximide
(CHX), the protein levels of Nrf2 in the absence or presence
of obacunone were examined. While the half-life of Nrf2
protein was 16.9 min in the absence of obacunone, the half-
life of Nrf2 protein in the presence of obacunone was
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Figure 1. Obacunone activates the Nrf2 pathway. (A) MDA-MB-231 cells were treated with the indicated dose of obacunone for 4
h, and cell lysate was subject to immunoblot analysis with anti-Nrf2, -Keap1, -GAPDH antibodies. (B) RAW264.7 cells were treated
with the indicated dose of obacunone for 4 h, and cell lysate was subject to immunoblot analysis. (C) LO2 cells were treated with the
indicated dose of obacunone for 4 h, and cell lysate was subject to immunoblot analysis. 5 μmol/L SF treatment was included as a
positive control in (A), (B), and (C). (D) MDB-MB-231 cells were either mock treated or treated with OC or SF for 24 h, then total RNAs
were extracted. Relative amounts of NQO1, MRP2, and HO-1 mRNAs were measured by qRT-PCR. The standard deviations were
calculated from triplicate samples. *P < 0.05, **P < 0.01 compared with its control. (E) RAW264.7 cells were either mock treated or
treated with OC or SF for 24 h, then total RNAs were extracted. Relative amounts of NQO1 and HO-1 mRNAs were measured by
qRT-PCR. The standard deviations were calculated from triplicate samples. *P < 0.05, **P < 0.01 compared with its control. (F) MDA-
MB-231 cells were mock treated or pretreated with 80 μmol/L OC or 5 μmol/L SF for 8 h, then challenged with 0.5 mmol/L H2O2 for
another 12 h. Cellular ROS level was detected by DCF staining and subsequent ﬂow cytometry. **P < 0.01, compared with its control.
##P < 0.01, compared with only H2O2-treated cells. (G) MDB-MB-231 cells were either mock treated or treated with 40 μmol/L OC for 4
h. 50 μmol/L cycloheximide was added and cells were lysed at the indicated time points. Cell lysates were subjected to immunoblot
analysis using anti-Nrf2 and anti-GAPDH antibodies. The intensity of the bands was quantiﬁed using Quantity One software and
plotted against the time after cycloheximide treatment. (H) 293T cells were co-transfected with the plasmids encoding the indicated
proteins. Cells were then treated with either 5 μmol/L SF or 60 μmol/L OC along with 10 μmol/L MG132 for 4 h before cell lysates were
collected for ubiquitination assay. Anti-Nrf2 immunoprecipitates were analyzed by immunoblot with anti-Nrf2 antibodies for detection
of ubiquitin-conjugated Nrf2.
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increased to 35.9 min, indicating that obacunone stabilizes
Nrf2 protein (Fig. 1G). To examine the impact of obacunone
on the ubiquitination of Nrf2, the cells were either mock
treated or treated with obacunone and the known Nrf2 acti-
vator SF. As expected, obacunone inhibits the ubiquitination
of Nrf2 similarly to the positive control SF (Fig. 1H). These
data support the notion that obacunone activates the Nrf2
pathway by stabilizing Nrf2 through inhibiting its ubiquitina-
tion and activating Nrf2-dependent responses.
Bleomycin is a chemotherapeutic drug used clinically for a
variety of human malignancies. It has been reported that the
administration of bleomycin often leads to lung injury and
ﬁbrosis in human patients. Bleomycin-induced lung injury in
mice is a well-established in vivo model of human pulmonary
ﬁbrosis (Hoshino et al., 2009). Numerous studies have
shown that the disturbance of the alveolar oxidant-antioxi-
dant balance may play a role in the pathogenesis of chronic
ﬁbrosis (Gasse et al., 2007). Therefore, considering that the
activation of Nrf2 results in antioxidant defense response,
bleomycin-induced lung injury can be used to evaluate the
therapeutic effects of Nrf2 activators,
We ﬁrst evaluated the conditions (dose and injection fre-
quency) that result in the activation of the Nrf2-dependent
response in the lung of mice. Forty-eight hours after sys-
temic delivery of obacunone (10 mg/kg, i.p.) in B6 mice, the
protein levels of Nrf2 in the lung were upregulated (Fig. 2A).
Consistent with this data, the mRNA levels of Nrf2 target
genes NQO1 and HO-1 were also increased (Fig. 2B).
Bleomycin (BLM) induced lung inﬂammation and ﬁbrosis
(Fig. 2C). For the analysis of lung ﬁbrosis, the collagen
content in the lung tissue was examined. When compared
with that in PBS-treated mice, collagen deposition (stained
blue by masson’s staining) was obviously increased in the
lung tissue of BLM-treated mice. Treatment of mice with
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Figure 2. Obacunone activates the pulmonary Nrf2 and inhibits bleomycin-induced lung ﬁbrosis. (A) Lung tissue lysates from
mice were subjected to immunoblot analysis with anti-Nrf2, -GAPDH antibodies. Lanes 1–3 indicate control samples, lanes 4–6
indicate samples from mice subjected to OC administration. (B) Total RNAs were extracted from freshly isolated lung tissue, and
relative amounts of NQO1, HO-1 mRNAs were measured by qRT-PCR. The standard deviations were calculated from triplicate
samples. **P < 0.01, compared with its control. (C) Each group shows a representative image of the lung tissue for HE staining
respectively. (D) The representative images of the lung tissue for Masson’s trichrome staining were shown. (E) HYP level in different
lung tissues was compared. *P < 0.05, control group vs. BLM-administrated froup; #P <0.05, BLM-administrated group vs. OC + BLM-
administrated group. (F) Relative mRNA expression of TGF-β was measured by real-time RT-PCR. **P < 0.01, control group
compared with BLE-administrated group; #P < 0.05, BLM-administrated group compared with OC + BLM-administrated group.
(G) Obacunone inhibits the BLM-induced lung ﬁbrosis as revealed by IHC analysis with anti α-SMA antibodies.
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obacunone signiﬁcantly reduces the collagen deposition in
the lung of BLM-administrated mice (Fig. 2D). To further
quantify for the levels of collagen deposition, we measured
the hydroxyproline content as an index of collagen, further
demonstrating that obacunone treatment signiﬁcantly redu-
ces the collagen deposition in BLM-administered mice
(Fig. 2E).
As additional indicators of tissue ﬁbrosis, we examined
the expression of α-SMA and TGF-β. We show that TGF-β
expression was signiﬁcantly upregulated in BLM-damaged
lung tissue, while obacunone treatment suppressed BLM-
induced TGF-β expression in the lung tissue (Fig. 2F).
Consistent with this ﬁnding, the number of α-SMA+ myoﬁ-
broblasts was signiﬁcantly increased in the lung tissue of
bleomycin-administered mice, obacunone treatment reduces
the number of α-SMA+ myoﬁbroblasts in the lung tissues of
bleomycin administered mice (Fig. 2G). In summary, these
ﬁndings demonstrate that obacunone can effectively protect
mice against BLM-induced lung ﬁbrosis.
BLM-induced damage causes inﬂammation in the lung,
leading to ﬁbrosis (Gasse et al., 2007; Hoshino et al., 2009).
To understand the mechanism how obacunone protects mice
against BLM-induced lung ﬁbrosis, we examined the impact
of obacunone on the BLM-induced inﬂammation in the lung of
B6 mice. We examined the mRNA levels of several cytokines
associated with pulmonary inﬂammation and ﬁbrosis. In
support of the notion that obacunone suppresses the BLM-
induced inﬂammation, obacunone treatment suppressed the
BLM-induced expression of inﬂammatory cytokines IL-6, IL-
17, MCP-1, but increased the mRNA levels of IFN-γ in the
lung (Fig. S2). In summary, these data support the notion that
obacunone suppresses BLM-induced inﬂammation and
ﬁbrosis of the lung by activating Nrf2 pathway.
With accumulating knowledge of the roles of Nrf2 in pro-
tecting against environmental insults, it becomes increas-
ingly important to identify and optimize Nrf2 activators that
can protect humans from various environmental insults. We
discovered a novel Nrf2 activator, a natural product oba-
cunone. In this context, we demonstrate that obacunone can
stabilize and activate Nrf2 by inhibiting Nrf2 ubiquitination. In
addition, we demonstrated that oxidative stress-induced lung
injury including inﬂammation and ﬁbrosis could be effectively
inhibited by systemic administration of obacunone. Similar to
another known Nrf2 activator sulforaphane, obacunone is
able to block ubiquitination and degradation of Nrf2, thus
resulting in the prolonged half-life of Nrf2. It remains tech-
nically challenging to identify the direct target of obacunone
in cells. Future effort will be devoted to understand the
mechanism how obacunone stabilizes Nrf2. One possibility
is that obacunone interferes with the function of Keap1, the
E3 ligase of Nrf2, leading to the stabilization of Nrf2. Another
possibility is that obacunone can disrupt the interaction
between Nrf2 and Keap1, leading to the stabilization of Nrf2.
Identiﬁcation of obacunone as a novel Nrf2 activator
broadens the choice for new chemopreventive compounds
against tissue damage or disease caused by various
environmental insults. Compared with other small molecule
Nrf2 activators, obacunone is a natural product with an
advantage in its safety. In support of this notion, obacunone
exhibits no apparent cytotoxicity in vitro and in vivo for the
limited time duration tested (Fig. S3). Taken together, our
experiments demonstrate the feasibility of preventing bleo-
mycin-induced lung injury by systemic administration of
obacunone, a novel potent Nrf2 activator. The obacunone-
mediated intervention may also be efﬁcacious for other types
of environmental insults and confer protection against tissue
damage in other organs.
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